NMDA receptor antagonists as analgesics: Focus on the NR2B subtype

Trends in Pharmacological Sciences

Volumn 22, Issue 12, 2001, Pages 636-642

  Chizh, Boris A ^a,c   Headley, P Max ^b   Tzschentke, Thomas M ^a  

^a GRÜNENTHAL GMBH   (Germany)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 5 PHOSPHONOVALERIC ACID; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6[[2 [4 [(4 FLUOROPHENYL)METHYL] 1 PIPERIDINYL]ETHYL]SULFINYL] 2 (3H) BENZOXAZOLONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; ALPHA (4 HYDROXYPHENYL) BETA METHYL 4 PHENYLMETHYL 1 PIPERIDINEPROPRANOL; ALPHA 1 ADRENERGIC RECEPTOR; APTIGANEL; CI 1041; DEXTRORPHAN; DIZOCILPINE; ELIPRODIL; GABAPENTIN; GACYCLIDINE; HISTAMINE H1 RECEPTOR; IFENPRODIL; ION CHANNEL; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; POLYAMINE; PROTON; RECEPTOR SUBUNIT; SEROTONIN RECEPTOR; SIGMA OPIATE RECEPTOR; TRAXOPRODIL; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTINOCICEPTION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BINDING; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0035577313     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01863-0     Document Type: Review

References (53)

1. The glutamate receptor ion channels
2. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors
3. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localization of NR2B subunit in dorsal horn
4. Antagonists selective for NMDA receptors containing the NR2B subunit
5. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors
6. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones
7. An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones
8. A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: Effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein
9. Pharmacological characterization of interactions of RO 25-6981 with the NR2B (2) subunit
10. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition
11. (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-pr opanol: A potent new neuroprotectant which blocks N-methyl-D-aspartate responses
12. Neurochemical pharmacology of CI-1041 (PD196860): A novel subtype selective NMDA antagonist
13. Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats
14. In vitro binding properties in rat brain of [3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits
15. Distinct synaptic and extrasynaptic NMDA receptors identified in dorsal horn neurones of the adult rat spinal cord
16. Supraspinal vs spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil
17. Potent analgesia induced in rats by combined action at PCP and polyamine recognition sites of the NMDA receptor complex
18. Involvement of spinal NMDA receptors in capsaicin-induced nociception
19. Genetic enhancement of inflammatory pain by forebrain NR2B overexpression
20. Molecular evidence for the involvement of NR2B subunit containing N-methyl-D-aspartate receptors in the development of morphine-induced place preference
21. Genetic enhancement of learning and memory in mice
22. Age-related deficit in NR2B subunit expression correlates with behavioral impairment in Fisher 344 rats
23. Peripheral excitatory amino acids
24. Antinociception and central NMDA antagonism by glycine B antagonists: Evidence for a peripheral mechanism
25. Enhancement of NMDA-induced current by the putative NR2B selective antagonist ifenprodil
26. Stimulus intensity, cell excitation and the N-methyl-D-aspartate receptor component of sensory responses in the rat spinal cord in vivo
27. Glutamate in CNS disorders as a target for drug development: An update
28. Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice
29. 3H]MK-801 binding to NMDA receptors in vivo and in vitro
30. Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist
31. Anti-allodynic and anti-hyperalgesic effects of the NR2B subunit-selective NMDA antagonist CI-1041 in rat models of inflammation and neuropathy
32. The effects of CI-1041 in two tests of analgesia: Acetic acid-induced writing test and formalin foot pad test
33. Systemic ketamine attenuates nociceptive behaviors in a rat model of peripheral neuropathy
34. The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy
35. Effects of a partial agonist and a full antagonist acting at the glycine site of the NMDA receptor on inflammation-induced mechanical hyperalgesia in rats
36. Different capability of N-methyl-D-aspartate antagonists to elicit EEG and behavioural phencyclidine-like effects in rats
37. Prepulse inhibition of the startle reflex in rats: Effects of compounds acting at various sites on the NMDA receptor complex
38. The self-administration of MK-801 can depend upon drug-reinforcement history and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys
39. Evaluation of the reinforcing effects of eliprodil in rhesus monkeys and its discriminative stimulus effects in rats
40. Measuring reward with the conditioned place preference paradigm: A comprehensive review of drug effects, recent progress and new issues
41. Effects of the non-competitive NMDA receptor antagonist ifenprodil on the morphine-induced place preference in mice
42. Is the discriminative stimulus produced by phencyclidine due to an interaction with N methyl-D-aspartate receptors?
43. A novel NMDA antagonist, MK-801, impairs performance in a hippocampal-dependent spatial learning task
44. Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice
45. CP101,606, an NR2B selective NMDA receptor antagonist, does not block hippocampal LTP
46. Neuroprotective NMDA antagonists: The controversy over their potential for adverse effects on cortical neuronal morphology
47. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy
48. Comparison of ketamine and pethidine in experimental and postoperative pain
49. Effects of gacyclidine, a non-competitive NMDA receptor antagonist, in human healthy volunteers
50. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers
51. Quality of life of patients with peripheral arterial obliterative disease treated with ifenprodil tartrate. Results of an ARTEMIS study
52. Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA antagonist
53. A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury